Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.2K
Overview
44.2K
Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies.

Virology journal·2026
Same author

Different SARS-CoV-2 Subvariants and Coagulation Markers Trend: A Retrospective Multicentric Study From Iranian Network for Research in Viral Diseases (INRVD).

Health science reports·2026
Same author

Epidemiology and Clinical Outcomes of HTLV-1: A Comprehensive Narrative Review of Endemic and Nonendemic Regions.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale·2026
Same author

Assessment of Awareness and Knowledge Regarding Human T-Lymphotropic Virus Type 1 (HTLV-1) Among Healthcare Workers at Imam Khomeini Hospital Complex, Tehran, in 2023-2024, A Cross-Sectional Descriptive-Analytical Study.

Health science reports·2026
Same author

Unmasking HAM/TSP: understanding HTLV-1-driven neurological disease.

Journal of neurovirology·2026
Same author

Human betaretrovirus (HBRV), homologous to mouse mammary tumor virus (MMTV), and human breast cancer: a significant epidemiological association.

Retrovirology·2026

Related Experiment Video

Updated: Jun 17, 2025

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

3.6K

HTLV-1 vaccination Landscape: Current developments and challenges.

Arash Letafati1,2, Mahshid Bahari2,3, Omid Salahi Ardekani2

  • 1Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Vaccine: X
|August 6, 2024
PubMed
Summary

Developing a Human T-lymphotropic virus type 1 (HTLV-1) vaccine is crucial for combating associated diseases. Research explores various vaccine platforms, facing challenges in long-term immunity and viral diversity.

Keywords:
ATLLHAM/TSPHTLV-1VaccinationVaccine

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.2K

Related Experiment Videos

Last Updated: Jun 17, 2025

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

3.6K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.2K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Human T-lymphotropic virus type 1 (HTLV-1) infects 5-10 million globally, linked to serious conditions like HAM/TSP and ATLL.
  • HTLV-1 also contributes to inflammatory conditions such as uveitis and dermatitis.
  • Effective vaccination strategies are needed to mitigate the global burden of HTLV-1 infection.

Purpose of the Study:

  • To review the current progress in Human T-lymphotropic virus type 1 (HTLV-1) vaccine development.
  • To highlight the diverse approaches being investigated for HTLV-1 vaccination.
  • To identify the key challenges and future directions in creating an effective HTLV-1 vaccine.

Main Methods:

  • Review of current scientific literature on HTLV-1 vaccine research.
  • Analysis of various vaccine platforms including viral vectors, DNA, protein/peptide, dendritic cell, and mRNA vaccines.
  • Assessment of immune responses targeted, such as cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs), and B cells.

Main Results:

  • Multiple vaccine strategies are under investigation, utilizing viral components to elicit immune responses.
  • Promising preliminary results have been observed across different platforms.
  • Significant challenges persist, including achieving long-term protective immunity and addressing viral diversity.

Conclusions:

  • Ongoing research shows promise for HTLV-1 vaccine development, exploring diverse platforms.
  • Overcoming challenges related to immunity duration and viral variability is critical for success.
  • Continued monitoring of advancements is essential for combating HTLV-1-associated diseases effectively.